Two new drugs for epilepsy.
D000328:Adult; D000927:Anticonvulsants / Q000627:therapeutic use*; D002220:Carbamazepine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D004347:Drug Interactions; D004827:Epilepsy / Q000188:drug therapy*; D006801:Humans; D007408:Intestinal Absorption / Q000187:drug effects; D007555:Isoxazoles / Q000627:therapeutic use; D000077287:Levetiracetam; D018697:Nootropic Agents / Q000627:therapeutic use*; D000078330:Oxcarbazepine; D010889:Piracetam / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D026941:Sodium Channel Blockers; D000078305:Zonisamide
D000927:Anticonvulsants; D007555:Isoxazoles; D018697:Nootropic Agents; D026941:Sodium Channel Blockers; D002220:Carbamazepine; D000077287:Levetiracetam; D000078305:Zonisamide; D000078330:Oxcarbazepine; D010889:Piracetam